Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dobson, Claire L ^a   Devine, Paul W A ^b   Phillips, Jonathan J ^c   Higazi, Daniel R ^a   Lloyd, Christopher ^a   Popovic, Bojana ^a   Arnold, Joanne ^a   Buchanan, Andrew ^a   Lewis, Arthur ^a   Goodman, Joanne ^a   Van Der Walle, Christopher F ^a   Thornton, Peter ^a   Vinall, Lisa ^a   Lowne, David ^a,e   Aagaard, Anna ^d   Olsson, Lise Lotte ^d   Wollberg, Anna Ridderstad ^d,f   Welsh, Fraser ^a   Karamanos, Theodoros K ^b   Pashley, Clare L ^b   Iadanza, Matthew G ^b   Ranson, Neil A ^b   Ashcroft, Alison E ^b   Kippen, Alistair D ^a,g   Vaughan, Tristan J ^a   Radford, Sheena E ^b   Lowe, David C ^a   more..

^a MEDIMMUNE LTD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e Immunocore Limited   (United Kingdom)

^f Uppsala BIO   (Sweden)

^g IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANIMAL; ANTIBODY SPECIFICITY; BIOPHYSICS; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; MUTATION; PROCEDURES; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; RAT; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PROPERTY; VISCOSITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOPHYSICAL PHENOMENA; CHROMATOGRAPHY, GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; HYDROGEN; MICE; MUTATION; ORGAN SPECIFICITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SURFACE PROPERTIES; VISCOSITY;

EID: 85007000932     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38644     Document Type: Article

References (54)

1. Reichert, J. M. Antibodies to watch in 2016. MAbs 8, 197-204 (2016
2. Vugmeyster, Y., et al. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-Abeta Ab2, in nonclinical species. Pharm. Res. 28, 1696-1706 (2011
3. Wu, H., et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007
4. Deng, R., et al Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3, 61-66 (2011
5. Hotzel, I., et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 4, 753-760 (2012
6. Sharma, V. K., et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc. Natl. Acad. Sci. USA 111, 18601-18606 (2014
7. Kelly, R. L., et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs 7, 770-777 (2015
8. Lahlou, A., Blanchet, B., Carvalho, M., Paul, M., & Astier, A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann. Pharm. Fr. 67, 340-352 (2009
9. Philo, J. S., & Arakawa, T. Mechanisms of protein aggregation. Curr. Pharm. Biotechnol. 10, 348-351 (2009
10. Saluja, A., & Kalonia, D. S. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int. J. Pharm. 358, 1-15 (2008
11. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289, 1-30 (2005
12. Chi, E. Y., et al. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colonystimulating factor. Protein Sci. 12, 903-913 (2003
13. Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 11, 99-109 (2014
14. Rosenberg, A. S. Effects of protein aggregates: an immunologic perspective. AAPS J. 8, E501-7 (2006
15. Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., & Trout, B. L. Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol. 391, 404-413 (2009
16. Obrezanova, O., et al. Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs 7, 352-363 (2015
17. Jacobs, S. A., Wu, S. J., Feng, Y., Bethea, D., & O'Neil, K. T. Cross-interaction chromatography: A rapid method to identify highly soluble monoclonal antibody candidates. Pharm. Res. 27, 65-71 (2010
18. Liu, L., Braun, L. J., Wang, W., Randolph, T. W., & Carpenter, J. F. Freezing-induced perturbation of tertiary structure of a monoclonal antibody. J. Pharm. Sci. 103, 1979-1986 (2014
19. Kohli, N., et al. A novel screening method to assess developability of antibody-like molecules. MAbs 7, 752-758 (2015
20. Pepinsky, R. B., et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 19, 954-966 (2010
21. Wu, S. J., et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23, 643-651 (2010
22. Seeliger, D., et al. Boosting antibody developability through rational sequence optimization. MAbs 7, 505-515 (2015
23. Arora, J., et al. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-Association of an IgG1 monoclonal antibody. MAbs 7, 525-539 (2015
24. Zhang, J., et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010
25. Daramola, O., et al. A high-yielding transient system: Coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. American Institue of Chemical Engineers Biotechnol. Prog. 30, 132-141 (2014
26. Phillips, J. J., et al. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs. J. Mol. Biol. 372, 1189-1203 (2007
27. Wales, T. E., & Engen, J. R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158-170 (2006
28. Kabat, E. A., & Wu, T. T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibodycombining sites. J. Immunol. 147, 1709-1719 (1991
29. Woods, L. A., Radford, S. E., & Ashcroft, A. E. Advances in ion mobility spectrometry-mass spectrometry reveal key insights into amyloid assembly. Biochim. Biophys. Acta 1834, 1257-1268 (2013
30. Snijder, J., & Heck, A. J. Analytical approaches for size and mass analysis of large protein assemblies. Annu. Rev. Anal. Chem. (Palo Alto Calif) 7, 43-64 (2014
31. Loo, J. Studying noncovalent protein complexes by electrospray ionization mass spectrometry. Mass Spectrometry Reviews 16, 1-23 (1997
32. Breuker, K., & McLafferty F. W. Stepwise evolution of protein native structure with electrospray into the gas phase, 10-12 to 102 s. Proc. Natl. Acad. Sci. USA 105, 18145-18152 (2008
33. Cromwell, M. E., Hilario, E., & Jacobson, F. Protein aggregation and bioprocessing. AAPS J. 8, E572-9 (2006
34. Roberts, C. J. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol. 32, 372-380 (2014
35. Clark, R. H., et al. Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs. MAbs 6, 1540-1550 (2014
36. Li, B., et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs 6, 1255-1264 (2014
37. Schoch, A., et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc. Natl. Acad. Sci. USA 112, 5997-6002 (2015
38. Igawa, T., et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel. 23, 385-392 (2010
39. Feyen, O., et al. Off-target activity of TNF-Alpha inhibitors characterized by protein biochips. Anal. Bioanal Chem. 391, 1713-1720 (2008
40. Bumbaca, D., et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 3, 376-386 (2011
41. Xu, Y., et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, highthroughput selection and analytical tool. Protein Eng. Des. Sel. 26, 663-670 (2013
42. Groves, M., et al. Affinity maturation of phage display antibody populations by ribosome display. J. Immunol. Methods 313(1-2), 129-139 (2006
43. Finch, D. K., et al. Whole molecule antibody engineering: generation of a high affinity anti-IL-6 antibody with extended pharmacokinetics. J. Mol. Biol. 411(4), 791-807 (2011
44. Persic, L., et al. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187, 9-18 (1997
45. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J., & Schubert, D. Size distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophysical Journal 82, 1096-111 (2002
46. Edgeworth, M. J., et al. Global and Local Conformation of Human IgG Antibody Variants Rationalizes Loss of Thermodynamic Stability. Angew. Chem. Int. Ed Engl. 54, 15156-15159 (2015
47. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011
48. Winn, M. D., Isupov, M. N., & Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122-133 (2001
49. Holland, D. R., Cousens, L. S., Meng, W., & Matthews, B. W. Nerve growth factor in different crystal forms displays structural flexibility and reveals zinc binding sites. J. Mol. Biol. 239, 385-400 (1994
50. Faber, C., et al. Three-dimensional structure of a human Fab with high affinity for tetanus toxoid. Immunotechnology 3, 253-270 (1998
51. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007
52. Murshudov, G. N., Vagin, A. A., & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997
53. Smart, O. S., et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D Biol. Crystallogr. 68, 368-380 (2012
54. Emsley, P., & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004